This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hassan, K. A. Articles by Mao, L. Search for Related Content PubMed PubMed Citation Articles by Hassan, K. A. Articles by Mao, L.

Clinical Significance of Cyclin B1 Protein Expression in Squamous Cell Carcinoma of the Tongue¹

Department of Thoracic/Head and Neck Medical Oncology [K. A. H., J. C. S., D. L., W. K. H., L. M.] and Department of Pathology [A. K. E-N.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: Cyclin B1 plays an important role in control of the G₂-M transition of the cell cycle. We have shown recently that overexpression of cyclin B1 is associated with poor outcome in patients with early stage squamous cell carcinoma (SCC) of the lung.

Experimental Design: To determine the role of cyclin B1 in SCC of the tongue, we analyzed tumor specimens from 41 patients with stage II–IV SCC of the tongue who underwent curative surgery using immunohistochemistry.

Results: The median follow-up of all patients was 83 months. Overexpression of cyclin B1 was observed in 15 (37%) of the 41 tumors, a similar frequency to that found in SCC of the lung. Patients whose tumors showed overexpression of cyclin B1 had a poor event-free survival compared with those lacking this feature (P = 0.04 by Log-rank test). Multivariate analysis of traditional clinical/pathological factors showed that cyclin B1 overexpression was an independent prognostic indicator.

Conclusions: Our study indicates that cyclin B1 is overexpressed in a subset of SCC of the tongue and is associated with a more aggressive biological behavior of the disease.

This article has been cited by other articles:

				H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn T Cell-Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease Clin. Cancer Res., February 15, 2005; 11(4): 1521 - 1526. [Abstract] [Full Text] [PDF]

				M. Rodriguez-Pinilla, J. L. Rodriguez-Peralto, R. Hitt, J. J. Sanchez, C. Ballestin, A. Diez, L. Sanchez-Verde, F. Alameda, and M. Sanchez-Cespedes Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8486 - 8492. [Abstract] [Full Text] [PDF]

				T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, and H. Kuwano The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer Ann. Onc., February 1, 2004; 15(2): 252 - 256. [Abstract] [Full Text] [PDF]

				K. A. Hassan, K. K. Ang, A. K. El-Naggar, M. D. Story, J. I. Lee, D. Liu, W. K. Hong, and L. Mao Cyclin B1 Overexpression and Resistance to Radiotherapy in Head and Neck Squamous Cell Carcinoma Cancer Res., November 15, 2002; 62(22): 6414 - 6417. [Abstract] [Full Text] [PDF]